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Refining Liver Safety Risk Assessment:
Application of Mechanistic Modeling and Serum
Biomarkers to Cimaglermin Alfa (GGF2) Clinical
Trials
DM Longo1, GT Generaux1, BA Howell1, SQ Siler1, DJ Antoine2, D Button3, A Caggiano3, A Eisen3,
J Iaci3, R Stanulis3, T Parry3, M Mosedale4,5 and PB Watkins4,5
Cimaglermin alfa (GGF2) is a recombinant human protein growth factor in development for heart failure. Phase I trials were
suspended when two cimaglermin alfa-treated subjects experienced concomitant elevations in serum aminotransferases
and total bilirubin, meeting current US Food and Drug Administration criteria for a serious liver safety signal (i.e., “Hy’s
Law”). We assayed mechanistic biomarkers in archived clinical trial serum samples which confirmed the hepatic origin of
the aminotransferase elevations in these two subjects and identified apoptosis as the major mode of hepatocyte death.
Using a mathematical model of drug-induced liver injury (DILIsym) and a simulated population, we estimated that the maxi-
mum hepatocyte loss in these two subjects was <13%, which would not result in liver dysfunction sufficient to significantly
increase serum bilirubin levels. We conclude that the two subjects should not be considered Hy’s Law cases and that mech-
anistic biomarkers and modeling can aid in refining liver safety risk assessment in clinical trials.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 In clinical trials, subjects experiencing rises in serum amino-
transferases and bilirubin above certain thresholds are consid-
ered “Hy’s Law cases”—the current gold standard liver safety
concern. The assumption is that serum bilirubin rises due to
global liver dysfunction secondary to hepatocyte death.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Can mechanistic biomarkers and mathematical modeling
determine the extent of hepatocyte loss and resultant impact on
serum bilirubin in two cimaglermin alfa-treated subjects who
met Hy’s Law Criteria?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 Mechanistic biomarkers and mathematical modeling deter-
mined the maximum hepatocyte loss experienced by the two
subjects would not cause a loss of global liver function sufﬁcient
to account for a signiﬁcant rise in serum bilirubin. Hence, these
subjects shouldn’t be considered typical Hy’s Law cases.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 This study illustrates the capability of mechanistic bio-
markers and mathematical modeling to improve liver safety risk
assessment by differentiating a toxic event from a more complex
interference with liver function that may be reversible.
Cimaglermin alfa is a recombinant version of naturally occurring
glial growth factor 2 (GGF2). Cimaglermin alfa acts at the cellu-
lar level on cardiomyocytes and neurons by interacting with the
epidermal growth factor receptor family members ERBB3 and
ERBB4. In phase I clinical trials, dose-related improvements in
cardiac function were observed in patients with heart failure fol-
lowing a single administration of cimaglermin alfa. However,
clinical trials were suspended when two cimaglermin alfa-treated
subjects experienced concomitant elevations in serum amino-
transferases and bilirubin, meeting the stopping criteria outlined
in the 2009 US Food and Drug Administration (FDA) Guidance
on Drug-Induced Liver Injury (DILI).1
The elevated liver chemistries in both subjects returned to near
baseline within 2 weeks and long-term follow-up demonstrated
no subsequent evidence of hepatic dysfunction. However, both
subjects experienced aminotransferase levels >33 upper limits of
normal (ULN) and total bilirubin >23 ULN. Because there was
no other evident cause for these events, these subjects ﬁt the crite-
ria for “Hy’s Law,” a term coined by Dr. Bob Temple of the
FDA based on Dr. Hy Zimmerman’s observation that
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hepatocellular injuries sufﬁcient to impair bilirubin excretion are
capable of causing potentially lethal consequences, i.e., at least a
10% rate of liver failure. Even a single “Hy’s Law case” in a clini-
cal trial database can result in termination of drug development
programs or failure to receive regulatory approval for marketing.2
Hy’s Law cases typically present with increases in serum ami-
notransferases (due to release during hepatocyte death) preceding
and rising to a much greater extent than elevations in total serum
bilirubin. This is consistent with the assumption that a large frac-
tion of total hepatocytes must die before there is sufﬁcient reduc-
tion in global liver function to result in a rise in serum bilirubin.
The two putative Hy’s Law cases observed in the cimaglermin
alfa clinical trials did not ﬁt this proﬁle, as total (and conjugated)
bilirubin rose concurrently with, and to a similar fold change as,
serum aminotransferases. Thus, the two putative cases differed
from typical Hy’s Law cases in which aminotransferase elevations
occur ﬁrst and are followed by a smaller elevation in serum
bilirubin.
Novel hepatic safety biomarkers such as microRNA-122
(miR-122), glutamate dehydrogenase (GLDH), caspase-cleaved
cytokeratin-18 (cc-K18), and full length keratin-18 (FL-K18)
have potential clinical utility, alongside traditional serum bio-
markers, in assessing hepatotoxicity.3 miR-122 and GLDH are
liver-speciﬁc biomarkers released during hepatocyte death. Kera-
tin 18 (K18) is abundantly expressed in epithelial cells including
hepatocytes. FL-K18 is passively released from necrotic cells. In
contrast, during apoptosis, caspase cleavage of K18 occurs result-
ing in cc-K18 release from apoptotic cells after loss of membrane
integrity. The ratio of cc-K18 to FL-K18 (the “apoptotic index”)
has been proposed to estimate the relative contributions of necro-
sis and apoptosis to cell death.4 Macrophage colony-stimulating
factor (CSF-1) represents a proregenerative biomarker that has
been shown to increase following partial hepatectomy in mice
and humans and to correlate with survival in acetaminophen-
induced hepatotoxicity.5
Recently, the FDA identiﬁed the development and use of com-
putational models as an important tool for assessing product
safety.6 Mechanistic, mathematical modeling can facilitate the
interpretation of liver safety biomarker data by incorporating bio-
marker release and clearance kinetics and linking back the results
to mechanisms underlying DILI. Previous work demonstrated
the successful application of DILIsym, a mechanistic model of
DILI, to aid in the interpretation of serum aminotransferase (but
not bilirubin) elevations observed in healthy volunteers in a
phase I clinical study.7
In the current study, serial serum samples collected from
phase I clinical trial subjects were assayed for miR-122, cc-K18,
FL-K18, GLDH, and CSF-1. DILIsym software8–11 was used to
interpret the kinetics of these biomarkers along with the tradi-
tional liver chemistries that had been measured in the trials. Find-
ings from this study indicate that the amount of hepatocyte loss
that likely occurred during treatment with cimaglermin alfa
(<13%) would be signiﬁcantly less than that required to cause
the observed elevations in serum bilirubin. Therefore, factors
other than hepatocyte death likely underlie the rise in serum bili-
rubin in cimaglermin alfa-treated subjects. Our data suggest that
the concomitant elevations in serum aminotransferases and total
bilirubin observed in the two subjects treated with cimaglermin
alfa were not indicative of typical Hy’s Law cases that would
identify severe liver injury.
RESULTS
Liver function test abnormalities in cimaglermin alfa-treated
subjects
Two phase I studies of cimaglermin alfa were conducted in
patients with heart failure. In the ﬁrst study, an elevation in
serum aminotransferases and total and conjugated bilirubin was
encountered in the 40th subject who received the highest
planned dose of 1.5 mg/kg (Table 1). In the second study, the
22nd of 28 planned subjects who received the highest planned
dose of 0.38 mg/kg also experienced elevations in serum amino-
transferases and total and conjugated serum bilirubin (Table 2).
In both cases, the biochemical abnormalities returned to near
baseline within 2 weeks; long-term follow-up demonstrated no
subsequent evidence of hepatic injury or dysfunction. However,
both subjects experienced aminotransferase levels >33 ULN
and total bilirubin >23 ULN with no other obvious cause than
cimaglermin alfa, thus satisfying Hy’s Law criteria, and further
development of cimaglermin alfa was put on hold.
Hy’s Law cases typically present as an increase in serum ami-
notransferases (due to hepatocyte necrosis) preceding and rising
to a greater extent than elevations of total serum bilirubin
(due to liver dysfunction). However, the pattern of enzyme ele-
vations observed in the two subjects described above did not
ﬁt this proﬁle, as total (and conjugated) bilirubin was elevated
concurrently and to a similar extent as serum aminotransferases
(Tables 1, 2).
Hepatic safety biomarker analysis
Five investigational safety biomarkers were analyzed in serial
serum samples archived from 12 subjects included in the phase I
cimaglermin alfa clinical studies (see Supplementary Table S1
for subject demographics). The subjects whose samples were ana-
lyzed include the two putative Hy’s Law cases as well as others
with elevated serum aspartate aminotransferase (AST)/alanine
aminotransferase (ALT) levels, and two placebo-treated subjects
with no AST/ALT elevations. Time-dependent elevations in lev-
els of serum biomarkers speciﬁcally associated with liver injury,
miR-122 (Figure 1a) and GLDH (Figure 1b), were observed in
four subjects, including the two subjects meeting Hy’s Law crite-
ria (Subjects 8 and 12 in Figure 1). The maximal observed values
for miR-122 and GLDH were comparable to those previously
reported in healthy adults receiving therapeutic doses of acet-
aminophen12 and heparins13 and are, on average, 253 lower
than elevations seen for serious DILI induced by acetaminophen
overdose.14 In all subjects, the increase in miR-122 returned to
baseline values and GLDH appeared to be returning to baseline
levels at the ﬁnal measurement on Day 28.
Elevated levels of cc-K18 (Figure 1c) and FL-K18 (Figure 1d)
were also observed in the same subjects that experienced eleva-
tions in miR-122 and GLDH. The time course of the elevations
was similar to that of miR-122 and appeared to be returning to
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Table 2 Liver chemistries for subject meeting Hy’s Law criteria in phase Ib trial
Study day
Actual values Multiples of ULNa
AST
(U/L)
ALT
(U/L)
DBIL
(mg/dL)
TBIL
(mg/dL)
ALP
(U/L) INR
AST
(35)
ALT
(60)
DBIL
(0.5)
TBIL
(1.2)
ALP
(125)
214b 48 56 0.3 1.5 110 1.4 1.4 0.9 0.6 1.3 0.9
22c 55 69 0.3 1.3 114 1.3 1.6 1.2 0.6 1.1 0.9
21c 53 65 0.2 1.1 113 1.3 1.5 1.1 0.4 0.9 0.9
0Ad 49 64 0.3 1.2 111 1.3 1.4 1.1 0.6 1.0 0.9
0Bd 48 64 0.4 1.6 114 1.3 1.4 1.1 0.8 1.3 0.9
1Ad 142 106 1.2 3.2 137 1.5 4.1 1.8 2.4 2.7 1.1
1Bd 150 112 2.2 4.8 139 ND 4.3 1.9 4.4 4.0 1.1
2Ad 169 130 3.5 6.4 160 1.6 4.8 2.2 7.0 5.3 1.3
2Bd 181 142 2.7 5.2 176 1.5 5.2 2.4 5.4 4.3 1.4
3 170 145 1.9 3.9 201 1.3 4.9 2.4 3.8 3.3 1.6
4 113 132 1.0 2.6 209 1.2 3.2 2.2 2.0 2.2 1.7
5 90 122 0.8 2.3 239 1.1 2.6 2.0 1.6 1.9 1.9
9 80 92 0.3 1.3 117 1.1 2.3 1.5 0.6 1.1 1.4
16 90 117 0.2 0.8 161 1 2.6 2.0 0.4 0.7 1.3
23 61 93 0.1 0.6 131 1 1.7 1.6 0.2 0.5 1.0
42 47 71 0.1 0.7 97 1.1 1.3 1.2 0.2 0.6 0.8
86 41 58 0.2 0.9 104 1.1 1.2 1.0 0.4 0.8 0.8
AST, aspartate transaminase; ALT, alanine transaminase; DBIL, direct bilirubin; TBIL, total bilirubin; ALP, alkaline phosphatase; INR, international normalized ratio; ULN,
upper limit of normal; ND, not determined.
aNumbers in parentheses are the upper limits of normal (ULN). bScreening. cBaseline. dA and B designate two samples taken at different times on the same study
day.
Table 1 Liver chemistries for subject meeting Hy’s Law criteria in phase Ia trial
Study day
Actual values Multiples of ULNa
AST
(U/L)
ALT
(U/L)
DBIL
(mg/dL)
TBIL
(mg/dL)
ALP
(U/L) INR
AST
(41)
ALT
(63)
DBIL
(0.3)
TBIL
(1.2)
ALP
(126)
216b 42 40 0.3 1.1 50 1 1.0 0.6 1.0 0.9 0.4
21c 42 30 0.4 1.2 53 1 1.0 0.5 1.3 1.0 0.4
0 57 33 0.5 1.0 50 ND 1.4 0.5 1.7 0.8 0.4
1 32 27 0.4 1.1 49 1 0.8 0.4 1.3 0.9 0.4
2 227 220 ND 4.6 94 ND 5.5 3.5 ND 3.8 0.7
3 243 233 ND 4.8 103 ND 5.9 3.7 ND 4.0 0.8
4 184 216 3.8 6.3 143 ND 4.5 3.4 12.7 5.2 1.1
8 62 130 0.8 2.0 146 1.1 1.5 2.1 2.7 1.7 1.2
15 45 77 0.4 1.3 108 ND 1.1 1.2 1.3 1.1 0.9
21 49 60 0.3 1.3 73 1.2 1.2 1.0 1.0 1.1 0.6
117 32 30 0.2 0.8 50 ND 0.8 0.5 0.7 0.7 0.4
AST, aspartate transaminase; ALT, alanine transaminase; DBIL, direct bilirubin; TBIL, total bilirubin; ALP, alkaline phosphatase; INR, international normalized ratio; ULN,
upper limit of normal; ND, not determined.
aNumbers in parentheses are the upper limits of normal (ULN). bScreening. cBaseline.
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baseline levels at the ﬁnal measurement. The absolute values for
the increase in both M30 (cc-K18) and M65 (cc-K18 and FL-
K18) were higher than previously reported in healthy adult vol-
unteers receiving recurrent therapeutic doses of acetaminophen12
but were signiﬁcantly lower than those observed in patients with
serious DILI due to acetaminophen overdose.15 The mathemati-
cal ratio of M30 to M65 is termed the “apoptotic index” and has
been recently proposed to estimate the relative proportions of
cell death by apoptosis and necrosis.4 Across all subjects with ele-
vated cc-K18 and FL-K18, the apoptotic index (calculated using
peak cc-K18 and peak FL-K18 values for each subject) ranged
from 0.53–0.76, suggesting that apoptosis was the major form of
cell death.
In three subjects (including one of the putative Hy’s law cases
and another subject with elevated miR-122 and GLDH), an
increase in the proregenerative biomarker CSF-1 was observed
(Figure 1e). The absolute values for the increase in CSF-1 was
lower than previously reported postoperative increases in serum
CSF-1 in partial hepatectomy patients.5
Simulations in the baseline human in DILIsym
The baseline human in DILIsym represents a typical normal,
healthy volunteer. We performed simulations in the baseline
human, using the hepatocyte life cycle and liver injury biomarker
submodels in DILIsym (Figure 2), to investigate the percent
hepatocyte loss associated with plasma ALT elevations in the
four subjects with the highest elevations in serum aminotransfer-
ases, including the two Hy’s Law cases. As described above, mech-
anistic biomarkers supported apoptosis as the major mode of
cimaglermin alfa-induced hepatocyte death. With apoptosis as
the mode of cell death, the simulated and observed serum ALT,
AST, and total bilirubin proﬁles for the four cimaglermin alfa
Figure 1 Serum levels of liver safety biomarkers (a) microRNA-122 (miR-122), (b) glutamate dehydrogenase (GLDH), (c) caspase-cleaved fragment of
K18 (cc-K18), (d) full length keratin-18 (FL-K18), and (e) macrophage colony stimulating factor (CSF-1). Serum samples were collected at four different
timepoints relative to cimaglermin alfa (or placebo) administration from 12 patients who participated in phase I clinical trials including two patients which
met FDA drug-induced liver injury (DILI) guidance stopping criteria (Subjects 8 and 12), as well as others with elevated serum aminotransferases that fell
short of meeting FDA DILI guidance stopping criteria (Subjects 1, 2, 3, 4, 7, 9, 10, 11), and two placebo-dosed individuals (Subjects 5 and 6).
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subjects are presented in Figure 3. Clinical data and simulation
results are also shown for the placebo-treated subject (Figure 3).
For comparison, the results with necrosis as the mode of simu-
lated cell death are shown in Supplementary Figure S1. There
was good agreement between simulated ALT proﬁles and clinical
data; this was by design, as plasma ALT data from the clinical
trial subjects were employed for optimization. Plasma AST levels,
which were not used for optimization, were also simulated and
compared favorably with the clinical data (Figure 3b, Supple-
mentary Figure S1). These results conﬁrmed that the
representation of biomarkers (i.e., ALT and AST) and the hepa-
tocyte life cycle within DILIsym reasonably recapitulated clini-
cally observed data.
The plasma bilirubin levels were simulated based on the pre-
dicted viable hepatocyte mass and compared to the clinical data
(clinical bilirubin data was not used for the optimization). No
signiﬁcant rise in bilirubin was predicted in the baseline human
simulations for the four cimaglermin alfa-treated subjects with
the highest serum aminotransferases levels (Figure 3c). The lack
of bilirubin elevations in the DILIsym simulations is not
Figure 2 Diagrams of serum alanine transaminase (ALT) (a), serum aspartate transaminase (AST) (b), and bilirubin (c) submodels within DILIsym
version 4B.
Figure 3 Observed and simulated plasma levels of (a) alanine transaminase (ALT), (b) aspartate transaminase (AST), and (c) bilirubin for the four cima-
glermin alfa-treated subjects and the placebo-treated subject included in the DILIsym analyses. Subjects included in the DILIsym analyses consist of two
subjects who met FDA DILI guidance stopping criteria (Subjects 8 and 12), as well as two subjects with elevated serum aminotransferases who fell short
of meeting FDA DILI guidance stopping criteria (Subjects 7 and 11), and one placebo-treated subject (Subject 6). Subjects 6, 7, 8, 11, and 12 were also
included in the set of 12 subjects included in the serum biomarker analysis (Figure 1). Simulations on the baseline human in DILIsym were performed
assuming 100% apoptosis as the cell death modality. (Analogous simulation results with 100% necrosis as the cell death modality are shown in Supple-
mentary Figure S1.) The ALT model was optimized to the cimaglermin alfa ALT clinical data. AST and bilirubin data were not used for the optimization;
plasma AST and bilirubin levels were simulated based on the amount of hepatocyte injury optimized to ALT dynamics. Closed black circles represent clini-
cal data. Solid red lines represent simulated results due to 100% apoptosis.
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consistent with the marked rise in serum bilirubin observed in
the two cimaglermin alfa-treated subjects who met Hy’s Law cri-
teria. In the simulations, hepatocyte loss of 60% was necessary
for total bilirubin to reach 6 mg/dL (i.e., the approximate biliru-
bin levels observed in both subjects who met Hy’s Law criteria).
While simulated bilirubin levels of 6 mg/dL could be achieved in
simulations of such substantial increases in hepatocyte loss, the
observed bilirubin kinetics could not be reproduced in the simu-
lations (simulated time to peak bilirubin was several weeks, while
observed peak bilirubin levels occurred within several days).
Predicted hepatocyte loss in the baseline human simulations
for the cimaglermin alfa-treated subjects ranged from 6–9%
when apoptosis was the mechanism of hepatocyte death. Lower
levels of cell loss were predicted when necrosis was the mode of
hepatocyte death (1–5%). Predicted hepatocyte loss for the
placebo-treated subject was 0%.
Hepatocyte loss in a simulated population (SimPops)
To estimate what peak percent hepatocyte loss could have
occurred if interpatient variability is considered, we explored a
simulated patient population (SimPops) which included variation
in parameters relevant to ALT dynamics and hepatocyte regener-
ation (Supplementary Table S2). Population analyses were
restricted to plasma ALT <500 U/L, or 2-fold higher than the
maximum serum ALT observed to date in cimaglermin alfa-
treated patients (233 IU/L). Estimated ranges of hepatocyte loss
at different plasma peak ALT levels over the representative time
frame of ALT elevations are presented in Table 3 and Figure 4.
For the representative cimaglermin alfa subject ALT dynamic
proﬁle, lower estimated cell loss was again predicted for 100%
apoptosis (Table 3, Figure 4a) vs. 100% necrosis (Table 3, Fig-
ure 4b). At the maximum plasma peak ALT observed in cima-
glermin alfa-treated patients (233 IU/L), the estimated
hepatocyte loss range was 6.6–12.4% with apoptosis as the cell
death modality and 2.7–7.8% with necrosis as the cell death
modality (Table 3). No bilirubin elevations were predicted for
this range of estimated hepatocyte loss (i.e., up to 12.4%).
The time required to regenerate lost hepatocytes was also
assessed in the SimPops for individuals losing up to 13% of hepa-
tocytes (simulated peak ALT levels <300 U/L). Following liver
loss of 13%, the recovery time to reach 95% viable liver mass
ranged from 13–42 weeks (Supplementary Figure S2).
DISCUSSION
DILI can have a major impact on clinical drug development pro-
grams. When liver safety concerns arise for new drug candidates,
development may be terminated or larger and longer clinical tri-
als may be required, increasing costs and potentially delaying
Table 3 Range of estimated (simulated) hepatocyte loss as a function of observed plasma peak alanine transaminase (ALT) range
in phase I cimaglermin alfa-treated subjects with 100% apoptosis or 100% necrosis as the cell death modality
Peak ALT range (U/L)
Hepatocyte loss (%)
estimated with 100% apoptosis
(lower bound – upper bound)
Hepatocyte loss (%)
estimated with 100% necrosis
(lower bound – upper bound)
1–100 0.0–7.0 0.0–2.8
101–200 4.9–9.9 2.7–6.2
201–300 6.6–12.4 2.7–7.8
Figure 4 Range of estimated hepatocyte loss as a function of observed plasma peak alanine transaminase (ALT) range in cimaglermin alfa subjects for
two different cell death modalities (100% apoptosis (a), 100% necrosis (b)). Dashed lines show the corresponding peak ALT bins for each of the four spe-
cific cimaglermin alfa phase I subjects. The five subjects included in the DILIsym analyses consist of two subjects whom met FDA DILI guidance stopping
criteria (Subjects 8 and 12), as well as two subjects with elevated serum aminotransferases who fell short of meeting FDA DILI guidance stopping criteria
(Subjects 7 and 11), and one placebo-treated subject (Subject 6). Subjects 6, 7, 8, 11, and 12 were also included in the set of 12 subjects included in
the serum biomarker analysis (Figure 2).
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patient access to new medications.16 Cimaglermin alfa is in devel-
opment for the treatment of chronic heart failure. The observa-
tion of two cimaglermin alfa-treated subjects meeting current
criteria for Hy’s Law cases resulted in a hold placed on the cima-
glermin alfa clinical development program due to liver safety con-
cerns. Here we utilized investigational, mechanistic liver safety
biomarkers in conjunction with mathematical modeling to reﬁne
the interpretation of clinical safety data from phase I clinical
studies of cimaglermin alfa.
Our observation that elevations in serum aminotransferases
were accompanied by elevations in miR122 and GLDH con-
ﬁrmed liver origin of the enzymes. The apoptotic index (cc-K18/
FL-K18) supported apoptosis as the major mode of cell death.
DILIsym modeling in a simulated population of patients encom-
passing variability in relevant parameters predicted that the maxi-
mum percent hepatocyte loss was <13% in patients completing
the phase I clinical trials. The estimated peak values for hepato-
cyte loss are in the range of what has been estimated to occur as a
result of asymptomatic and reversible elevations in serum amino-
transferases observed in healthy adults during recurrent therapeu-
tic doses of acetaminophen12 or heparins13 rather than clinically
important hepatotoxicity. It is of note that both of the putative
Hy’s Law cases did experience symptoms at the time of the bio-
chemical abnormalities; one experienced nausea and abdominal
pain and the other experienced ﬂu-like symptoms.
Published data also suggest that minimal changes in liver func-
tion are expected at the level of hepatocyte loss we estimated for
cimaglermin alfa patients. For example, in the early 1980s liver
biopsies were performed acutely on 70 acetaminophen overdose
patients.17 Substantial elevations in serum prothrombin time and
peak bilirubin levels were observed only when reductions in the
estimated viable hepatocyte volume fraction exceeded 25% (i.e.,
changes in function were not evident for cell loss less than
25%).17 Overall, these data suggest that the maximum hepato-
cyte loss estimated using serum ALT data from cimaglermin alfa
phase I subjects was less than the extent necessary to detectably
interfere with liver function.
Further, there were no increases in simulated serum bilirubin
levels for the predicted hepatocyte loss in the two putative Hy’s
Law cases, while serum levels of bilirubin exceeding 53 ULN
were observed. The inconsistencies between simulated bilirubin
levels and bilirubin clinical data, and the observation that the
clinical elevations were largely conjugated bilirubin, would be
consistent with the hypothesis that a transient selective defect in
bilirubin transport rather than global liver dysfunction was
responsible for the rise in serum bilirubin in the cimaglermin
alfa-treated subjects who met Hy’s Law biochemical criteria. This
hypothesis is supported by recent in vitro data demonstrating
transient cimaglermin alfa-mediated effects on hepatic physiology
related to bilirubin and bile acid transport.18 In that study, global
gene expression proﬁling in primary human hepatocytes exposed
to cimaglermin alfa identiﬁed 50% reductions in bilirubin
transporters and bile acid conjugating enzymes that may impact
the biliary clearance of conjugated bilirubin.
One limitation of the current study is that the percent hepato-
cyte loss estimated by DILIsym has not been validated
experimentally. A second limitation is a lack of experimental data
to assess potential impacts of cimaglermin alfa on hepatocellular
ATP levels. Given the absence of such data, ATP levels were not
varied in the simulations. Another limitation is that the patients
included in the phase I studies received a single dose of cimagler-
min alfa, while chronic therapy would be required in the target
population. In addition, in the current study DILIsym was not
parameterized for heart failure patients. While liver function test
(LFT) abnormalities are common in heart failure patients, little
is currently known about the effects of heart failure on hepatic
function.19–21 In the current study the subjects had normal base-
line LFTs. Reduced baseline hepatic function may be more
likely in heart failure patients with abnormal baseline LFTs.
Hepatocyte loss of 13% may be more clinically meaningful in
patients with impaired liver function prior to treatment with
cimaglermin alfa.
In conclusion, the mechanistic biomarker data and DILIsym
analyses, suggest that less than 13%, primarily apoptotic, hepato-
cyte loss occurred in cimaglermin alfa-treated subjects with serum
liver enzyme elevations in phase I clinical trials. This level of
hepatocyte loss is not consistent with global liver dysfunction
leading to the rise in serum bilirubin. It therefore seems likely
that the rise in serum bilirubin observed in the two subjects was
due to transient defects in bilirubin transport rather than loss of
functional hepatocytes. Therefore, these two cases do not repre-
sent typical Hy’s Law cases and should not be interpreted as nec-
essarily indicating that cimaglermin alfa has a serious liver injury
potential. These ﬁndings suggest that mechanistic hepatic safety
biomarkers, combined with mathematical modeling, can improve
the interpretation of traditional liver safety signals. To fully
understand both the value and limitations of these novel
approaches, broad application to clinical trials is necessary. Efforts
are currently under way by several groups, including the SAFE-T
(Safer and Faster Evidence-based Translation) consortium, the
IMI (Innovative Medicines Initiative), and the DILI-sim Initia-
tive, to understand how mechanistic biomarkers and modeling
can improve the assessment of liver injury.
METHODS
Cimaglermin alfa phase I studies
Clinical development of cimaglermin alfa was initiated with Study
NCT01258387: “A Phase 1, Double-Blind Placebo-Controlled Study of
Single Ascending Doses of GGF2 in Patients with Left Ventricular Dys-
function and Symptomatic Heart Failure.” This study was designed to
evaluate the safety, tolerability, pharmacokinetics, and immunogenicity
of single administrations of cimaglermin alfa in patients with systolic left
ventricular dysfunction and symptomatic heart failure. Cimaglermin alfa
or placebo was administered as a single intravenous infusion to 40 sub-
jects. Doses started at 0.007 mg/kg cimaglermin alfa and escalations were
planned up to 1.512 mg/kg cimaglermin alfa. Subjects were hospitalized
from Day –1 to Day 2 with safety tests and evaluations conducted at var-
ious timepoints throughout the study. The following serum liver chemis-
tries were measured using standard assays on a clinical chemistry
analyzer: ALT, AST, direct bilirubin, total bilirubin, and alkaline phos-
phatase. Prothrombin time was also measured and used to calculate
international normalized ratio (INR). Subjects were discharged with
instructions to return for their ﬁrst postdose evaluation on Day 8 6
2 days.
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Study NCT01944683: “A Double-Blind Pharmacokinetic Interaction
Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo
on Midazolam Pharmacokinetics in Patients with Heart Failure” was
designed to continue evaluating the safety and tolerability of cimagler-
min alfa in patients with heart failure and to evaluate potential drug–
drug interactions. The maximum of three dose levels selected for exami-
nation was 0.38 mg/kg cimaglermin alfa, a concentration 4-fold less than
the dose at which a limiting toxicity was observed previously (i.e., one
subject met Hy’s law criteria at the 1.512 mg/kg dose in the ﬁrst study)
and was selected with input from an external panel of cardiologists and
hepatologists. Subjects were hospitalized from Day –1 to Day 8, and
daily assessments with safety laboratory tests, including the liver chemis-
tries described above, performed to assess for evidence of hepatotoxicity
and other biochemical abnormalities. Subjects were discharged on
Day 8 (5 days after receiving cimaglermin alfa) after all study procedures
were completed.
Hepatic safety biomarker analyses
Hepatic safety biomarker analyses were performed on a total of 48 serum
samples collected at four different timepoints (Days 0, 8, 14, 28) relative
to cimaglermin alfa (or placebo) administration from 12 subjects who
participated in the two phase I clinical trials. The subjects whose samples
were analyzed include the two putative Hy’s Law cases (Subjects 8 and
12) as well as others with elevated serum AST/ALT levels (Subjects 1, 2,
3, 4, 7, 9, 10, 11), and two placebo-treated subjects who did not experi-
ence AST/ALT elevations (Subjects 5, 6).
Serum samples were analyzed for miR-122, GLDH, FL-K18, cc-K18,
and CSF-1. miR-122, GLDH, and K18 isoforms M30 (cc-K18) and
M65 (both cc-K18 and FL-K18) were quantiﬁed as previously
described.22 CSF-1 was analyzed as previously described.5
DILIsym version 4B
DILIsym is a mechanistic, mathematical model of DILI (DILIsym Serv-
ices Inc., http://www.dilisym.com),8–11 developed and maintained
through the DILI-sim Initiative, a public-private partnership involving
scientists in academia, industry, and the FDA. In the current study,
DILIsym version 4B was utilized to estimate the amount of hepatocyte
loss in cimaglermin alfa-treated subjects with elevated ALT/AST, and to
simulate circulating bilirubin levels for the inferred amount of hepato-
cyte loss (see details in Baseline human simulations, below). DILIsym
analyses were performed on the four clinical trial subjects with the high-
est elevations in serum aminotransferases, including the two subjects
meeting Hy’s Law criteria.
ALT, AST, and bilirubin submodels of DILIsym version 4B
The current work utilized the hepatocyte life cycle and liver injury bio-
marker submodels of DILIsym version 4B. The ALT submodel is shown
in Figure 2a. Plasma ALT levels in DILIsym are determined by the rates
of hepatocyte injury and plasma ALT clearance. When hepatocyte death
occurs via primary necrosis, cellular ALT is released and enters the circu-
lation. ALT is also released during apoptosis, except when apoptosis
occurs at very low levels (see details in the Supplementary Informa-
tion). The ALT submodel consists of three compartments. The Liver
compartment represents temporary association of ALT with cells as
necrosis or apoptosis occurs. The Plasma compartment represents sys-
temic circulation. Creation of the Intermediate compartment was
required to optimize serum ALT dynamics observed in clinical response
to several hepatotoxic compounds15,23–25 and may represent the ALT in
the interstitial space, the Space of Disse, or the liver sinusoids. The clear-
ance of ALT is driven by a speciﬁed half-life.26 Clearance of ALT occurs
in all three compartments, as the exact mechanism and locations of liver
enzyme clearance is not yet elucidated.27,28 Hepatocyte levels of ALT
taken from the literature were used to represent the amount of ALT
released per necrotic or apoptotic cell.29,30
The AST submodel structure within DILIsym version 4B is similar to
the ALT submodel structure (Figure 2b). AST is also cleared with a
speciﬁed half-life.26 Hepatocellular release of AST occurs with necrosis
and apoptosis, as described above for ALT. Cellular levels of AST deter-
mined from the literature have been used to represent the amount of
AST released per necrotic or apoptotic cell.31,32
Changes in plasma bilirubin levels in DILIsym version 4B are deter-
mined by alterations in its hepatic clearance, as the formation of biliru-
bin from red blood cells is constant and dictated by homeostatic levels
(Figure 2c). In DILIsym version 4B, bilirubin clearance depends on the
fraction of viable hepatocytes (as well as the level of hepatocellular ATP,
which was not varied in the current study). Bilirubin model parameters
were optimized using clinical data from the literature.17,33,34
Supplementary Table S3 shows the parameter values for the ALT,
AST, and bilirubin submodels for the baseline human in DILIsym ver-
sion 4B.
Baseline human simulations
DILIsym was used to approximate the ALT elevations observed in
phase I clinical studies following treatment with cimaglermin alfa by sim-
ulating dynamic changes in liver necrosis or apoptosis in the baseline
human. For each cell death modality (necrosis or apoptosis), the amount
of cell death was optimized (individually for each subject) to achieve
plasma ALT time-course proﬁles that are similar to the observed ALT
proﬁles for each subject. The hepatocellular mechanisms [drug exposure,
hepatotoxicity mechanisms, adenosine triphosphate (ATP) depletion,
etc.] leading up to cell loss were not considered herein. Instead, the
method for simulating hepatocellular loss was an empirical, direct necro-
sis or direct apoptosis signal.
Assessing variability with a simulated human population
(SimPops)
To account for the interindividual variability in ALT response and hepa-
tocyte regeneration from a given level of hepatocyte loss, a simulated
human population (SimPops) that consists of 300 healthy individuals
was employed. In this SimPops, variability was introduced in the parame-
ters relevant to ALT dynamics and hepatocyte regeneration. The range
and variance of each parameter was obtained from the literature, and
simulated hepatocyte loss and plasma ALT levels in the SimPops were
validated using clinical data from the literature.17,24 A list of parameters
varied and their upper and lower bounds in the SimPops are presented
in Supplementary Table S2. The SimPops was used for subsequent sim-
ulations of necrosis and apoptosis-induced increases in circulating ALT.
Additional Supporting Information may be found in the online version of
this article.
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